This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Celldex Therapeutics Initiates Pilot Study In Dense Deposit Disease

Stocks in this article: CLDX

PHILLIPSBURG, N.J., July 1, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported that the first patient has been dosed in the Company's pilot study of CDX-1135 (a soluble form of human complement receptor type 1) in dense deposit disease (DDD). DDD is an ultra-rare, progressive kidney disease that ultimately results in kidney failure in the majority of affected individuals. DDD is caused by dysregulation of the C3 Convertase, a major early component of the alternative pathway of complement. CDX-1135 has been shown to inhibit complement activation and has yielded promising results in an animal model of DDD and in a single patient with DDD that was treated under a compassionate use protocol.

The open-label study will enroll up to five patients (ages four and older) from clinical centers across the United States to determine the CDX-1135 dose level required to normalize alternative complement activity on an individual patient basis. Potential effects on renal function will also be assessed. Patients will initially be treated at the University of Iowa under the leadership of Richard J.H. Smith, MD and Carla M. Nester, MD. If selected complement levels normalize on therapy, patients may be able to return to their local treatment center to continue in the study. Dr. Smith, a widely recognized expert in DDD, is Professor of Otolaryngology and Internal Medicine and the Director of the Molecular Otolaryngology and Renal Research Laboratories (MORL) at the University of Iowa. MORL maintains the largest DDD patient database in the world. Dr. Nester, also a member of MORL, is an Assistant Professor at the University of Iowa, trained in adult and pediatric nephrology.

"CDX-1135 is a much needed and exciting entrant to the dense deposit disease field," said Dr. Smith. "There are currently no treatments and nearly half of all patients progress to end-stage renal disease within 10 years of presentation, often spending the rest of their lives on dialysis. In a mouse model of dense deposit disease, CDX-1135 has been shown to control the abnormal complement activity and to reduce deposits in the kidneys. Short term use of CDX-1135 in a patient with dense deposit disease and end-stage renal disease was well-tolerated and normalized the activity of the alternative complement pathway. We are optimistic that if we can control complement activation earlier in the disease course and at a critical step in the complement pathway, CDX-1135 may be able to restore kidney function and provide long term disease control—a long-awaited outcome for patients, their families and physicians."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs